In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...

GSK’s potential “functional cure” for hepatitis B drug has proven its worth in a pair of hotly anticipated phase 3 studies, ...

The B-Well 1 and B-Well 2 trials evaluated the safety, efficacy, and durability of bepirovirsen in nucleos(t)ide analogue-treated participants with CHB.

"MetaVia OXM analogue agonist meets endpoints in Phase Ib weight loss trial" was originally created and published by Clinical ...

The market underappreciates TENX's late-stage pipeline and risk-adjusted asset value; we recommend buying ahead of Phase 3 ...

Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.

A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...

Fred Hutchinson Cancer Center-led investigators found that higher patient-reported fatigue before cancer treatment aligned ...

Patients who have comorbid COPD with heart failure and ischemic heart disease have increased health care resource use and higher mortality.

Zenas BioPharma shares fell sharply after the company reported favorable Phase 3 study results for obexelimab in immunoglobulin G4-related disease. The stock fell 56% to $15.22. Despite Monday's ...

During a live event, Matthew Lunning, DO, interpreted long-term outcomes of the ZUMA-7 and TRANSFORM trials.

A comprehensive genetic investigation led by Dr. Feng Liu at Tianjin Medical University General Hospital has uncovered ...